Crespi M, Demarzo MG, Brunacci M, Pellegatta G, Ferrando F, Ballestrero A, Grillo F, Savarino V, Giannini EG

Language: English
References: 23
Page: 1072-1077
PDF size: 480.94 Kb.

ABSTRACT

Chronic hepatitis C (HCV) virus infection may be associated with several non-hepatic manifestations, mainly driven by chronic immune stimulation, such as mixed cryoglobulinemia and Non-Hodgkin’s Lymphoma. This association has been proved by several meta-analyses and some interventional studies demonstrating that antiviral treatment may be effective in inducing HCV-associated lymphoma regression. The recent advent of direct acting antivirals (DAAs) in the therapeutic armamentarium of HCV infection made possible treatment of patients with advanced liver disease. Here we report on a rare association of a cirrhotic patient with HCV and Waldenström’s Macroglobulinemia with severe cryoglobulinemia, who had already failed an interferon-based antiviral regimen, whose haematologic disease was ameliorated by HCV eradication following treatment with sofosbuvir and simeprevir with ribavirin, and where successful treatment was accompanied also by consistent improvement in liver function and parameters of portal hypertension.

REFERENCES

1. 1.Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol 2017; 14: 122-32.

2. 2.Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, et al. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol 2017; 2: 427-34.

3. 3.European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017; 2: 325-36.

4. 4.Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 2016; 65: 524-31.

5. 5.Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 2017; 65: 804-12.

6. 6.Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, Farinati F, Giannini EG, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017; 45: 160-8.

7. 7.Arcaini L, Merli M, Volpetti S, Rattotti S, Gotti M, Zaja F. Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. Clin Dev Immunol 2012; 2012: 638185.

8. 8.Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, Visentini M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood 2016; 128: 2527-32.

9. 8.Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology 2003; 125: 1723-32.

10. 9.Merli M, Carli G, Arcaini L, Visco C. Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol 2016; 22: 8447-58.

11. 10.Giordano TP, Henderon L, Landgren O, Chiao EY, Kramer JR, El-Serag H, Engels EA. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2017; 297: 2010-17.

12. 11.de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008; 6: 451-8.

13. 12.Nipp R, Mitchell A, Pishko A, Metjian A. Waldenström Macroglobulinemia in hepatitis C: case report and review of the current literature. Case Rep Oncol Med 2014; 2014: 165670.

14. 13.Mihaila RG. Hepatitis C virus - associated B cell non-Hodgkin’s lymphoma. World J Gastroenterol 2016; 22: 6214-23.

15. 14.Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a metaanalysis. J Viral Hep 2016; 23: 536-44.

16. 15.Slager SL, Benavente Y, Blair A, Vermeulen R, Cerhan JR, Costantini AS, Monnereau A, et al. Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014; 2014: 41-51.

17. 16.Leleu X, O’Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, et al. Hepatitis C viral infection is not associated with Waldenström’s macroglobulinemia. Am J Hematol 2007; 82: 83-4.

18. 17.Senín A, Broquetas T, Cañete N, Lens S, Londoño MC, Ferraro M, Forns X, et al. Aplastic anemia and severe myelosuppression with boceprevir or simeprevir-containing hepatitis C virus treatment. Ann Hepatol 2017; 16: 312-17.

19. 18.Álvarez-Ruiz SB, García-Río I, Aragüés M, Fraga J, Locertales Pueyo J, Fernández-Herrera J, García-Díez A. Leucocytoclastic vasculitis, hepatitis C virus-associated mixed cryoglobulinaemia with biclonal gammopathy and Waldenström macroglobulinaemia. Br J Dermatol 2004; 151: 937-9.

20. 19.Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, et al. Treatment recommendations from the Eighth International Workshop on Waldenstrom’s Macroglobulinemia. Blood 2016; 128: 1321-8.

21. 20.Giannini EG, Peck-Radosavljevic M. Platelet dysfunction: status of thrombopoietin in thrombocytopenia associated with chronic liver failure. Semin Thromb Hemost 2015; 41: 455-61.

22. 21.Giannini EG, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31: 502-8.

23. 22.Kondili LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE 2017; 12: e0185728.